Trial Profile
A safety study of telaprevir, peginterferon alfa-2a and ribavirin for the treatment of hepatitis C (HCV) in liver transplant recipients with recurrent cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 18 Dec 2015 New trial record